Global contract research organisation (CRO) Broughton has expanded its cannabinoid testing capabilities.
The company can now deal with cannabigerol (CBG) and cannibigerolic acid (CBGA), which add to the company's CBD and THC testing capacity.
This service expansion reflects an increase in demand and interest for cannabinoid products, which may offer health benefits across several therapeutic areas.
This includes neuroprotection, inflammation management and infection control.
As the cannabinoid market continues to grow, the need for reliable testing services is becoming increasingly important, as it can ensure the consistency, purity and safety of healthcare products.
CBGA is a chemical precursor to both CBD and THC, and although it isn't psychoactive, it has shown significant promise in reducing anxiety, inflammation and bacterial infections.
“Testing for CBG and CBGA is essential for manufacturers looking to develop high-quality, compliant and research-backed products,” explained Beccy Bell, associate director of laboratory services at Broughton.
“With regulatory interest in minor cannabinoids increasing, ensuring these products have validated analytical testing is critical for product development and compliance.”
According to Broughton, CBG and CBGA testing is a necessity for regulatory compliance and market regulators. "Regulations are continuing to evolve, so precise cannabinoid profiling is required to meet legal standards,"
"In many jurisdictions, validated testing methods might be required for legal market entry and accurate cannabinoid quantification ensures batch consistency and maintains product integrity," added Bell.
Broughton's testing scheme will also screen for potential contaminants such as heavy metals, pesticides, residual solvents and microbial contamination.
